Answers to Everyday Practice Challenges in HIV Medicine
A Phone-a-Friend CME Series – Volume 2
Clinical Practice Guidelines
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
Long COVID or post-COVID conditions.
Centers for Disease Control and Prevention (CDC).
Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association.
Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, Stone NJ, Bailey AL, et al. Circulation. 2019;139(25):e1046-e1081.
Clinician Resources
ASCVD Risk Estimator Plus.
American College of Cardiology.
Ward 86 long-acting injectable antiretroviral protocol.
Getting to Zero San Francisco.
HIV Drug Resistance Database
Stanford University.
HIV drug interactions.
University of Liverpool.
Medications for Substance Use Disorder
Substance Abuse and Mental Health Services Administration (SAMHSA)
Patient and Caregiver Resources
AIDSMap Resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
Suggested Readings
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) From dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance.
Acosta RK, Willkom M, Andreatta K, et al. J Acquir Immune Defic Syndr. 2020;85(3):363-371.
Cognitive impairment in people living with HIV in the ART era: A Review.
Alford K, Vera JH. British Medical Bulletin. 2018;127(1):55-68.
Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A longitudinal analysis.
Aletaris L, Roman PM. J Subst Abuse Treat. 2015;57:1-8.
Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC) +dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
Bosch B, Akpomiemie G, Chandiwana N, et al. Clin Infect Dis. 2022; ciac949.
First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic.
Christopoulos KA, Grochowski J, Mayorga-Munoz F, et al. Clin Infect Dis. 2022; ciac631.
Factors associated with resilience among Black women living with HIV and histories of trauma.
Dale SK, Reid R, Safren SA. J Health Psychol. 2021;26(5):758-766.
The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals.
Ehrenkranz P, Rosen S, Boule A, et al. PLoS Med. 2021;18(5):e1003651.
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.
Eggers C, Arendt G, Hahn K, et al. J Neurol. 2017;264(8):1715-1727.
Phase 3 study of ibalizumab for multidrug-resistant HIV-1.
Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.
The conundrum of 'long-COVID-19': a narrative review.
Garg M, Maralakunte M, Garg S, et al. Int J Gen Med. 2021;14:2491-2506.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Gupta SK, Berhe M, Crofoot G, et al. Lancet HIV. 2023;10(1):e15-e23.
Switching to bictegravir/emtrictabine/tenofovir alafenamide in Black americans with HIV-1: a randomized phase 3b, multicenter, open-label study.
Hagins D, Kumar P, Saag M, et al. J Acquir Immune Defic Syndr. 2021;88(1):86-85.
Gender and sexual identity in adolescence: A mixed-methods study of labeling in diverse community settings.
Hammack PL, Hughes SD, Atwood JM, et al. J Adolesc Res. 2021;37(2):167-220.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.
Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap.
McArthur JC, Steiner J, Sacktor N, et al. Ann Neurol. 2010;67(6):699-714.
Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits Are Independently Associated with All-Cause Mortality.
Mugavero MJ, Westfall AO, Cole SR, et al. Clin Infect Dis. 2014;59(10):1471-1479.
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.
Neesgaard B, Greenberg L, Miró JM, et al. Lancet HIV. 2022;9(7):e474-e485.
Changes in weight and BMI with first-line doravirine-based therapy.
Orkin C, Elion R, Thompson M, et al. AIDS. 2021;35(1):91-99.
Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.
Paton NI, Musaazi J, Kityo C, et al. N Engl J Med. 2021;385(4):330-341.
Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-CoV-2 infection.
Peluso MJ, Spinelli MA, Deveau T-M, et al. AIDS. 2022;36(12):F7-F16.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, et al. Lancet. 2019;393(10189):2428-2438.
Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.
Rosenthal J, Tyor W. J Neurovirol. 2019;25(5):673-685.
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.
Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1380-1390.
Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.
Ethnic inequalities in mental health and socioeconomic status among older women living with HIV: result from the PRIME Study.
Solomon D, Tariq S, Alldis J, et al. Sex Transm Infect. 2022;98(2):128-131.
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. BMJ 2017;357:j1550.
Nirmatrelvir and the risk of post-acute sequelae of COVID-19.
Xie Y, Choi T, Al-Aly Z. medRxiv. 2022:11.03.22281783.
A Phone-a-Friend Peer Consult Series
A Phone-a-Friend Peer Consult Series
A Phone-a-Friend Peer Consult Series
A Phone-a-Friend Peer Consult Series
A Phone-a-Friend Peer Consult Series—Volume 2
A Phone-a-Friend Peer Consult Series—Volume 2
A Phone-a-Friend Peer Consult Series—Volume 2
A Phone-a-Friend Peer Consult Series—Volume 2
A Phone-a-Friend Peer Consult Series—Volume 2
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
Best Practices for Screening, Diagnosis, and Management
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
From the Airway Epithelium to Improved Patient Outcomes
Exercising Best Practices for Hospitalized Patients
Accelerating Diagnosis and Treatment
